Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 112   

Articles published

JNJ 101.35 -1.07 (-1.04%)
price chart
Johnson & Johnson Expects Lucrative Return on Drug Pipeline
Johnson & Johnson is predicting big returns from its prescription drug business, both financially and medically, as it develops treatments and strategies to intervene earlier and prevent or reduce the damage from several conditions, including Alzheimer ...
Johnson & Johnson Pegs Its Long-Term Growth Potential On Prevention  Forbes
Johnson & Johnson Seeks to Deliver 10 Blockbusters
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) might be stuck in a bit of a trading range over the past year, but that in no way reflects that its growth is at a standstill.
Johnson & Johnson's Schizophrenia Drug Wins FDA Approval
Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, developed the atypical antipsychotic Invega Trinza, which was granted priority review in January.
Johnson & Johnson''s Schizophrenia Drug Gains FDA''s ...  Nasdaq
Johnson & Johnson (JNJ) Announces FDA Approval of Invega Trinza as ...
Johnson & Johnson's Piping-Hot Pipeline
We believe that Johnson & Johnson is positioned for solid growth, driven by strength of its pharmaceuticals business, recovery in the consumer segment and market stabilization coupled with share gain in medical devices and diagnostics.
Johnson & Johnson and Achillion in $1.1 Billion Tie-Up
Under the exclusive global collaboration and licensing agreement, Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary becomes responsible for all costs of developing and selling the treatment regimens.
Achillion Pharmaceuticals (ACHN) And Johnson & Johnson (JNJ): Here's ...  Smarter Analyst
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?  Benzinga
Johnson & Johnson (JNJ) Walks Away Fairly Unscathed In The Risperdal Case
The original penalty called for a payment of $1.1 billion - one of the largest penalties handed over to Johnson & Johnson. Plaintiffs argued that Johnson & Johnson deliberately downplayed risks associated with the drug and at the same time tricked ...
Johnson & Johnson PT Raised to $112.00 at Jefferies Group (JNJ)  Dakota Financial News
Raymond James: Johnson & Johnson Has 'Innovation'  Benzinga
Johnson & Johnson Just Stepped Up Its Hepatitis C Game
As Gilead Sciences leads the market with $12.4 billion in sales last year, Johnson & Johnson (NYSE: JNJ ) is pairing its money with Achillion's (NASDAQ: ACHN ) technology to create a less invasive, more effective drug that could change the market ...
Johnson & Johnson and Reckitt Benckiser K-Y Jelly deal in tight spot with CMA
The Competition and Markets Authority (CMA) has expressed its concern over the potential purchase of the K-Y Jelly brand by Reckitt Benckiser (RB) from Johnson & Johnson, saying that the price of sexual lubricant could slip to new highs. Slough-based ...
KY Jelly buyout could push up prices of lubricant, competition watchdog warns  The Guardian
U.K. Regulator Says Reckitt's K-Y Acquisition Would Raise Prices  Bloomberg
Johnson & Johnson Takes On Gilead Sciences in Hep C... Again
A host of companies are knee-deep in developing new, more effective treatments, but few have been as successful as Gilead Sciences (NASDAQ: GILD ) and Johnson & Johnson (NYSE: JNJ ) . Less than two years ago, the two biotech giants were locked in a ...
Massive cancer philanthropy fraud, a global backlash again Sovaldi cost ...  MedCity News
Johnson & Johnson: Here's Where the Growth Will Come From
At its Pharma Business Review, Johnson & Johnson highlighted the depth of its pharma pipeline that is capable of sustaining a growth trajectory that exceeds the pharma industry average.